Pathogen-Directed Therapy: The Evidence Behind the Guide

A 64-year-old man with diabetes was admitted three days ago with fever and a urinary infection. His blood culture is back: Escherichia coli, with a long list of antibiotics and a small number beside each. The intern runs her finger down the list, finds the smallest number, and says, “Ciprofloxacin. It has the lowest MIC, so it must be the strongest.” This is an illustrative case, not a real patient.

By the end of this article you will know why that reasoning fails, and how to read the number properly. You will also know how to choose between drugs that are all marked sensitive.

1. An MIC Is Not a Score

First, what the number is. The MIC is the minimum inhibitory concentration: the smallest amount of the drug that stopped the organism growing in the laboratory. The commonest error in reading a culture report is comparing MIC values between drugs of different classes. They are not on the same scale, and an MIC means something only against the breakpoint for that one drug.

“So how do I compare them?” Ask how far each MIC sits below what the drug can actually reach in the patient. The tool used to work one through:

An Escherichia coli isolate comes back ciprofloxacin sensitive at an MIC of 0.25 mcg/mL and cefoperazone-sulbactam sensitive at 16 mcg/mL. Ciprofloxacin is not therefore the more potent option. A standard intravenous dose of ciprofloxacin reaches a peak serum concentration of about 3 to 4 mcg/mL, so an MIC of 0.25 leaves a narrow margin. Cefoperazone at a standard dose reaches above 150 mcg/mL, against which an MIC of 16 is left far behind.

The point is not the arithmetic of one pair of drugs. It is that each number must be read against its own drug: its own breakpoint, and the level that drug reaches at a standard dose. Where the drug must reach, and what the patient can tolerate, come next.

2. The Same Isolate Can Be Susceptible and Resistant at Once

“How can one organism be both?” Because the breakpoint depends on where the infection is. CLSI publishes two sets of pneumococcal penicillin breakpoints: meningeal susceptible at an MIC of 0.06 mcg/mL or less, non-meningeal susceptible at 2 mcg/mL or less. An isolate at 0.5 is therefore resistant if it came from cerebrospinal fluid and susceptible if it came from sputum. The organism has not changed; the concentration achievable at the site has.

This is why a laboratory report must say which breakpoint set was applied. It is also why a national susceptibility figure quoted without that qualifier can be actively misleading. Here is the example the tool used to give:

ICMR AMRSN 2024 reports 100 per cent pneumococcal penicillin susceptibility by non-meningeal breakpoints, and among 8 cerebrospinal fluid isolates only 2 of 8 were susceptible by meningeal ones.

One hundred per cent sounds reassuring. In meningitis, it is not.

3. Choosing Between Agents That Are All Reported Sensitive

Back to our patient’s report, which marks several drugs S. The tool asks four questions, in order:

1. Compartment penetration. Can the molecule reach the infected space? Echinocandins do not reach the eye, the central nervous system or the urine. Daptomycin is inactivated by pulmonary surfactant. Macrolides do not cross the blood-brain barrier.
2. Bactericidal requirement. Endocarditis, meningitis and profound neutropenia need a bactericidal agent.
3. Collateral disruption. Ceftriaxone and clindamycin both carry a substantial association with Clostridioides difficile colitis.
4. Host toxicity. A beta-lactam is preferred over an aminoglycoside or a polymyxin wherever renal function is borderline.

4. What the Report Never Says

A susceptibility panel tests what was requested. It does not warn that Proteus, Morganella, Providencia and Serratia are intrinsically resistant to the polymyxins and to tigecycline, that Listeria is intrinsically resistant to every cephalosporin, or that Mucorales are intrinsically resistant to voriconazole. The tool prints the intrinsic profile beside every result for that reason.

5. The National Picture, and How to Read It

“Why does the tool show national figures if I have the patient’s own report?” Because they tell you what the next patient’s report is likely to show. They also tell you how far to trust an empiric choice made before the report comes. The tool’s figures come from the ICMR Antimicrobial Resistance Research and Surveillance Network Annual Report 2024, the eighth edition. It covers 99,027 culture-positive isolates from tertiary care hospitals. The report’s own caveat matters. Because the network collects data from tertiary care hospitals, it is not reflective of community levels of resistance and should not be extrapolated to community settings.

The tool now prints each organism’s figures in the result when that organism is chosen. Here they are together:

Three readings matter more than the individual numbers, and the tool keeps them. Methicillin resistance in Staphylococcus aureus has risen steadily across eight years of surveillance. That makes empiric anti-MRSA cover defensible for severe staphylococcal sepsis, and makes de-escalation to a beta-lactam on an MSSA report the step where the mortality benefit sits. Carbapenem susceptibility in Klebsiella is close to a coin toss in a tertiary intensive care unit. That does not make a carbapenem the wrong empiric choice, but it does make the 48-hour review compulsory. And vancomycin resistance differs tenfold between the two clinical enterococci, so species identification changes the answer.

6. The Common Mistake

The common mistake is the one our intern made: reading the smallest MIC as the strongest drug. It is easy to see why. A smaller number looks like a stronger drug. It isn’t. Each MIC must be read against its own breakpoint and against what the drug can reach at the site of infection.

Back to Our Patient

His E. coli is reported sensitive to several drugs. The MICs cannot be ranked against one another. So the choice runs through the four questions. The drug must reach the blood and the urine, it should carry the least collateral damage, and it must suit his kidneys. The tool, given the organism, the site and the setting, prints the regimen and the intrinsic profile beside it.

Try This

A pneumococcus from cerebrospinal fluid has a penicillin MIC of 0.5 mcg/mL. The report says S. Is it? Illustrative case.

Answer. Not for meningitis. At 0.5 it is susceptible only by the non-meningeal breakpoint (2 mcg/mL or less). By the meningeal breakpoint (0.06 mcg/mL or less) it is resistant. Ask the laboratory which set it applied.

Take-Home Points

• Never compare MICs between drugs of different classes: read each against its own breakpoint.
• The same isolate can be susceptible in sputum and resistant in cerebrospinal fluid; ask which breakpoint set was used.
• Between drugs all marked S, choose by penetration, the need to kill, collateral damage and the patient’s organs.
• Intrinsic resistance is not on the report: know it, or let the tool print it.
• National surveillance figures come from tertiary hospitals; do not carry them to the community.

For the basics of antibiotics and resistance in plain words, see the Understanding Antibiotics series, written for patients (Part 3 is on resistance). For choosing before the culture is back, Empirical Antibiotics in India: The Evidence Behind the Pathway.

Declaration: the author built and maintains the tool. It is free to use. The figures in this article are those the tool carried in its Evidence tab on 5 November 2026, each from the source the tool names. The illustrative cases follow the tool’s rules; check the tool’s result for a real patient.

References

1. Indian Council of Medical Research. Annual Report, Antimicrobial Resistance Research and Surveillance Network, January 2024 to December 2024. 8th ed. New Delhi: ICMR; 2025.
2. Indian Council of Medical Research. Treatment Guidelines for Antimicrobial Use in Common Syndromes. 2nd ed. New Delhi: ICMR; 2019.
3. Infectious Diseases Society of America. Guidance on the Treatment of Antimicrobial-Resistant Gram-Negative Infections. Version 5.0. Arlington: IDSA; 30 July 2026.
4. Harris PNA, Tambyah PA, Lye DC, et al. Effect of piperacillin-tazobactam vs meropenem on 30-day mortality for patients with E coli or Klebsiella pneumoniae bloodstream infection and ceftriaxone resistance: the MERINO randomized clinical trial. JAMA. 2018;320(10):984-994.
5. Central TB Division, Ministry of Health and Family Welfare, Government of India. National Guidelines for Management of Drug Resistant TB. New Delhi: MoHFW.
6. Department of Health Research and Indian Council of Medical Research. Guidelines for Diagnosis and Management of Rickettsial Diseases in India. New Delhi: DHR-ICMR; 2015.
7. Varghese GM, Dayanand D, Gunasekaran K, et al. Intravenous doxycycline, azithromycin, or both for severe scrub typhus. N Engl J Med. 2023;388(9):792-803.
8. Liu C, Bayer A, Cosgrove SE, et al. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis. 2011;52(3):e18-e55.
9. Rybak MJ, Le J, Lodise TP, et al. Therapeutic monitoring of vancomycin for serious methicillin-resistant Staphylococcus aureus infections: a revised consensus guideline of ASHP, IDSA, PIDS and SIDP. 2020.
10. Pappas PG, Kauffman CA, Andes DR, et al. Clinical practice guideline for the management of candidiasis: 2016 update by the Infectious Diseases Society of America. Clin Infect Dis. 2016;62(4):e1-e50.
11. Chakrabarti A, Sood P, Rudramurthy SM, et al. Incidence, characteristics and outcome of ICU-acquired candidemia in India. Intensive Care Med. 2015;41(2):285-295.
12. Johnson S, Lavergne V, Skinner AM, et al. Clinical practice guideline by the Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America: 2021 focused update guidelines on management of Clostridioides difficile infection in adults. Clin Infect Dis. 2021;73(5):e1029-e1044.
13. World Health Organization. Guidelines for Diagnosing, Preventing and Managing Cryptococcal Disease Among Adults, Adolescents and Children Living with HIV. Geneva: WHO; 2022.
14. Patel A, Agarwal R, Rudramurthy SM, et al. Multicenter epidemiologic study of coronavirus disease-associated mucormycosis, India. Emerg Infect Dis. 2021;27(9):2349-2359.